Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 11/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204453 | 1.00 | GRIA4 (0.44) | GRIA4GRIA2NPSR1NAMPTMEN1 | |
| SCHEMBL10116175 | 0.84 | GRIA4 (0.42) | GRIA4GRIA2NPSR1NAMPTLMNA | |
| SCHEMBL14418518 | 0.83 | NAMPT (0.40) | GRIA4GRIA2NPSR1NAMPTMEN1 | |
| SCHEMBL14424201 | 0.83 | NAMPT (0.40) | GRIA4GRIA2NPSR1NAMPTMEN1 | |
| SCHEMBL13204426 | 0.82 | PTPN1 (0.56) | NPSR1NAMPTMEN1LMNAKMT2A | |
| SCHEMBL10114938 | 0.82 | PTPN1 (0.56) | NPSR1NAMPTMEN1LMNAKMT2A | |
| SCHEMBL13204438 | 0.81 | SMN1; SMN2 (0.49) | NPSR1NAMPTMEN1LMNAKMT2A | |
| SCHEMBL10114959 | 0.81 | SMN1; SMN2 (0.49) | NPSR1NAMPTMEN1LMNAKMT2A | |
| SCHEMBL10114976 | 0.81 | NAMPT (0.44) | GRIA2NPSR1NAMPTMEN1LMNA | |
| SCHEMBL13204454 | 0.81 | NAMPT (0.44) | GRIA2NPSR1NAMPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | GRIA4 335/4885GRIA2 334/4885NPSR1 8/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | GRIA4 372/4885GRIA2 358/4885NPSR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.